Effects of hydroxyurea on CNV induction in the mouse germline by Arlt, Martin F. et al.
Research Article
Effects ofHydroxyurea onCNV Induction in theMouseGermline
Martin F. Arlt,1Sountharia Rajendran,1SandraN.Holmes,1KathleenWang,1Ingrid L.Bergin,3
SamreenAhmed,1Thomas E.Wilson1,2 and ThomasW.Glover1*
1Department of Human Genetics, University of Michigan, Ann Arbor, Michigan
2Department of Pathology, University of Michigan, Ann Arbor, Michigan
3Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, Michigan
Copy number variants (CNVs) are important in
genome variation and genetic disease, with new
mutations arising frequently in the germline and
somatic cells. Replication stress caused by aphidi-
colin and hydroxyurea (HU) is a potent inducer of
de novo CNVs in cultured mammalian cells. HU is
used extensively for long-term management of
sickle cell disease. Here, we examined the effects
of HU treatment on germline CNVs in vivo in male
mice to explore whether replication stress can act
as a CNV mutagen in germline mitotic divisions as
in cultured cells and whether this would support a
concern for increased CNV mutations in offspring
of men treated with HU. Several trials of HU admin-
istration were performed by oral gavage and sub-
cutaneous pump, with CNVs characterized in
C57BL/6 x C3H/HeJ hybrid mouse offspring by
microarray and mate-pair sequencing. HU had a
short half-life of ~14 min and a narrow dose win-
dow over which studies could be performed while
maintaining fertility. Tissue histopathology and
reticulocyte micronucleus assays verified that doses
had a substantial tissue and genetic toxicity. CNVs
were readily detected in offspring that originated
in both paternal and maternal mouse strains, as de
novo and inherited events. However, HU did not
increase CNV formation above baseline levels.
These results reveal a high rate of CNV mutagen-
esis in the mouse germline but do not support the
hypothesis that HU would increase CNV forma-
tion during mammalian spermatogenesis, per-
haps due to highly toxic effects on sperm
development or experimental variables related
to HU pharmacology in mice. Environ. Mol.
Mutagen. 59:698–714, 2018. © 2018 Wiley
Periodicals, Inc.
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INTRODUCTION
Sickle cell disease (SCD) is the most common inherited
blood disorder in humans, affecting approximately 100,000
people in the United States and millions of people world-
wide (Lopez et al., 2010). SCD is most commonly caused
by a single inherited point mutation in the β-globin chain
of hemoglobin, resulting in expression of HbS in erythro-
cytes. The disease is characterized by a lifelong hemolytic
anemia with a greatly increased risk for acute medical com-
plications and accrual of organ damage (Bonds, 2005).
Chronic treatment problems include increasingly difficult
transfusion management and addiction to medications used
to treat painful vaso-occlusive crises.
Hydroxyurea (HU) is the most extensively used Food
and Drug Administration (FDA)-approved drug for long-
term management of SCD in adults and children and is
used to treat some thalassemias and cancers (Ware and
Aygun, 2009; Steinberg, et al., 2010; Madaan, et al., 2012;
Algiraigri and Kassam, 2017). Extended HU treatment
leads to increased expression of fetal hemoglobin (HbF)
and a reduced fraction of sickle hemoglobin (HbS) in
erythrocytes, thereby decreasing the rate of painful crises
and ameliorating disease severity (Charache, et al., 1995).
The mechanisms of action for HbF induction are not
completely understood. Presumably, HU causes suppres-
sion of erythroid progenitors and cell stress signaling,
which leads to recruitment of erythroid progenitors with
increased HbF levels (Agrawal, et al., 2014). The short-
term toxicities of HU are minimal, and a recent report on
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the long-term effects of HU treatment in a 17.5-year
follow-up of adults undergoing HU therapy found no dif-
ferences in the incidences of stroke, organ dysfunction,
infection, or cancer between treated individuals and con-
trols (Steinberg, et al., 2010). Thus, HU is a valuable and
effective therapeutic agent for SCD in adults (Ware and
Aygun, 2009; Steinberg, et al., 2010).
HU has both cytotoxic and genotoxic effects leading to
concerns about potential effects in treated patients and off-
spring. Few reproductive studies have been performed for
HU despite important potential effects on reproduction and
fetal development. Treated males typically have reduced
testicular indices, semen quality, sperm counts, and serum
testosterone levels (Modebe and Ezeh, 1995). There is also
evidence that HU administration is associated with
increased risk of leukemia in patients treated for myelopro-
liferative disorders (Weinfeld, et al., 1994; Kiladjian, et al.,
2006; Mizutani, et al., 2010). Recent studies using alkaline
comet and micronucleus assays found that patients treated
with HU had a significant increase in DNA damage in leu-
kocytes and erythrocyte precursors (Friedrisch, et al., 2008;
Flanagan, et al., 2010). It remains to be determined whether
these genotoxic effects extend to the germline.
We previously showed that HU is a potent inducer of de
novo copy number variants (CNVs) in a human cell culture
system at low doses (100–300 μM) comparable to the
plasma level achieved in treated human patients (Arlt et al.,
2011a,b). CNVs are generally defined as deletions or dupli-
cations ranging in size from tens to millions of base pairs.
Tens of thousands of normal polymorphic CNVs have now
been described throughout the genome of healthy individ-
uals and represent the major component of human genomic
variation (Sudmant, et al., 2015). In addition, spontaneous
or de novo CNVs arise frequently in the germline and are
an important and frequent cause of genetic and develop-
mental disorders (Zhang et al., 2009; Lee and Scherer,
2010). Despite their importance the risk factors involved in
CNV formation remain unknown, but, like all classes of
mutation, will likely include exposure to precipitating envi-
ronmental mutagens and inherited genetic predispositions.
The presumed mechanism of action of HU in CNV induc-
tion is its well-described indirect impairment of replication
fork progression by direct inhibition of ribonucleotide reduc-
tase, an enzyme involved in the synthesis of deoxynucleotide
triphosphates (dNTPs). This inference extends from related
experimental evidence that replication stress can induce CNVs
in mammalian cells (Arlt et al., 2009; Arlt et al., 2011a,b; Arlt
et al., 2012, 2014). Specifically, partial inhibition of replica-
tion with the DNA polymerase inhibitor aphidicolin (APH)
induces a high frequency of de novo CNVs in cultured mam-
malian cells with nearly identical features to those induced by
HU (Arlt et al., 2009). No CNVs induced by HU or APH
in vitro contained large stretches of homology indicative of
nonallelic homologous recombination (NAHR), which medi-
ates the formation of recurrent CNVs. Rather, junction
sequences displayed at most short microhomologies indicative
of either end joining or replicative template switching mecha-
nisms, such as MMBIR (Hastings et al., 2009). These junction
features, as well as the large size of experimentally induced
CNVs (median 186 kb) are consistent with descriptions of
non-recurrent CNVs, a major class of both normal and
disease-associated CNVs in humans (Conrad et al., 2010a,b).
These combined observations suggest a common mechanism
for most CNVs arising in the human germline and those
induced by replication stress in cell culture.
Importantly, while recurrent CNV formation by NAHR
occurs in meiosis during homolog pairing, constitutional
nonrecurrent CNVs are much more likely to occur in the
mitotic divisions within or leading to formation of the
germline, prior to meiosis itself. This inferred mitotic cell
origin has important implications for the genetic and envi-
ronmental factors involved in nonrecurrent CNV formation
and for their study. For example, the fact that the male
germline undergoes mitotic divisions leading to mature
sperm throughout adulthood while females complete germ-
line mitotic divisions in a short window during fetal devel-
opment predicts a male sex bias in risk, including from
adult exposures to mutagenic environmental agents. In this
context, it is noteworthy that we observed CNV induction
in vitro after treatments lasting only one to three cell divi-
sions. Adult men are treated with HU for years, which
spans many rounds of mitotic cell divisions leading from
prospermatogonia to primary spermatocytes.
In this study, we administered HU to adult male mice and
measured CNV formation in their offspring using genomic
methods to inform two related questions. First, we sought to
test our general hypothesis that replication stress will act as
a CNV mutagen in germline mitotic divisions in the same
manner as in cultured somatic cells. Second, we sought to
determine whether data from a mouse model would support
a concern for increased formation of de novo genomic alter-
ations in the sperm and offspring of men treated long-term
with HU during their reproductive years.
MATERIALS ANDMETHODS
Mouse Strains, Acquisition andBreeding
Animal use was reviewed and approved by the Institutional Animal
Care and Use Committee (IACUC) University of Michigan; protocol
PRO00006521. Animal husbandry was provided by the staff of the Uni-
versity of Michigan Unit for Laboratory Animal Medicine (ULAM) under
the guidance of supervisors who are certified by the American Association
for Laboratory Animal Science (AALAS). Veterinary care was provided
by ULAM faculty members and veterinary residents. The University of
Michigan is accredited by the Association for Assessment and Accredita-
tion of Laboratory Animal Care, International (AAALAC, Intl) and the
animal care and use program conforms to the standards of “The Guide for
the Care and Use of Laboratory Animals,” Revised 2011. The University
of Michigan has filed an assurance statement on these matters with the
Office of Laboratory Animal Welfare (OLAW). All procedures used fol-
lowed ULAM guidelines.
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For HU administration by gavage, male C57BL/6 J mice 22 days of age
at arrival were purchased from Jackson Laboratories (Bar Harbor, ME). For
HU administration by microinfusion pumps, male C57BL/6 J mice between
35 and 49 days of age at arrival were purchased from Jackson Laboratories
(Bar Harbor, ME) or Charles River Laboratories (Wilmington, MA). Female
C3H/HeJ mice for breeding to treated and control males were purchased
from Jackson Laboratories (Bar Harbor, ME).
Following the treatment window, each treated C57BL/6 J male was bred
to two untreated C3H/HeJ females for seven days, after which the females
were removed to separate cages. When pups were born, they were counted
and visually examined for physical abnormalities. The pups were allowed to
grow for 17–21 days and then euthanized. During this time, they were mon-
itored for any visible signs of physical or behavioral abnormalities (none
noted). Two pups from each litter were arbitrarily chosen for CNV analysis.
In addition, any pups that appeared runted, deformed, or sick were also ana-
lyzed in the event that a CNV led to the unhealthy phenotype.
HUAdministration byOralGavage and Subcutaneous
Pumps
For oral administration, the animals were dosed by oral gavage twice
daily 9 hours apart for 56 days, starting at 28 days of age. The animals
were weighed and arbitrarily assigned into treatment and control groups.
Body weights were collected each morning prior to dosing, and daily dose
volumes were calculated based on the most recent body weight. Well-
being of the mice was evaluated and clinical observations were recorded
twice daily at the time of dosing. At the end of the treatment regimen,
mice were allowed to recover for one day before being mated.
iPRECIO continuous infusion pumps, model number SMP-300 were
used for subcutaneous administration of HU. Pumps were programmed to
pump at a rate of 4 μl/hour. Pump implantation was conducted following
institutional guidelines for rodent aseptic surgery. The mice were anesthe-
tized in a rodent anesthesia induction chamber with isoflurane (2.5%) and
oxygen (1 l) and placed in an anesthesia mask for surgical prep and sur-
gery. The surgical area was clipped with electric clippers using a #50 sur-
gical blade and cleaned with Nolvasan surgical scrub and sterile saline.
The pumps were implanted subcutaneously. The antenna and hose of the
pump was tied together with 5–0 PDS and 7 mm wound clips were used
to close the incision. An application of sterile surgical glue (Indermil) was
applied to the incision before placing the animal in a recovery cage.
Pumps were refilled twice daily via injection through the pump’s fill port.
Mice were weighed prior to each pump refill, with each dose concentration
calculated prior to refill based on the previous recorded weight. A second
surgery was performed at the end of the 14-day treatment window to
remove the pumps. At the end of the treatment regimen, mice were
allowed to recover for 35 days before being mated. Untreated control mice
did not receive pumps.
Pharmacokinetic Assessment of PlasmaHULevels
Blood samples were taken from each mouse by cardiac puncture after
euthanasia with CO2. The blood was shipped on dry ice overnight to the
Research Triangle Institute (Research Triangle Park, NC) for quantitation
of plasma HU levels using high-performance liquid chromatography tan-
dem mass spectrometry with electrospray ionization.
HistologicAssessment of Testes and Epididymides
Tissues for histology were fixed for 48 hours in 10% neutral buffered
formalin and then processed to paraffin by standard methods using an
automated tissue processor. Decalcification of bone marrow sections was
performed using a formic acid-based decalcifying agent (Immunocal,
Decal Chemical Corporation). Tissues were mounted onto glass slides and
stained with hematoxylin and eosin on an automated histostainer. Tissues
were evaluated by light microscopy using published, standard criteria for
lesions of the male reproductive system in rodents (Creasy DM, 2002).
Evaluation was performed by a board-certified veterinary pathologist
blinded to the experimental groups (treated and control) at the time of
evaluation. Severity grades for testicular and epididymal lesions was based
on the following scale: 0: no alteration, 1: minimal (<5% tubules affected),
2: mild (5–25% tubules affected), 3: moderate (26–50% tubules affected),
4: marked (51–75% tubules affected), 5: severe (>75% tubules affected).
This scale is similar to standard 5-point grading scales used for the histo-
logical evaluation of testicular lesions (Creasy DM, 2002) apart from the
use of a more conservative (5–25% as opposed to 10–25%) lower thresh-
old for mild changes in our study.
CNVDetection andCharacterization byMicroarray
For all genomic analyses, DNA was isolated from tail snips of selected
pups using the Blood and Cell Culture DNA Mini Kit (Qiagen, German-
town, MD). In early studies, this DNA was subjected to CNV detection by
Nimblegen mouse MM9 whole-genome tiling UX3 microarrays. As a
comparative method, a reference DNA was required for which we used a
single female C57BL/6 x C3H/HeJ hybrid animal. Array analysis was per-
formed by custom software designed to sensitively detect copy number
differences unique to just one pup. We first dropped chrY, which was
uninformative given our female reference DNA and applied a median nor-
malization individually to all other chromosomes per sample to account
for DNA content differences in male vs. female animals. All chromosomes
thus had an adjusted median probe log reference ratio (LRR) of zero. We
next examined the LRR values across all analyzed mouse samples at each
probe and tentatively assigned each sample as copy number neutral (within
2.5 standard deviations of the chromosome mean), gain or loss relative to
the chromosome. We then applied a second normalization such that the
median sample within the majority copy number group was set to an LRR
of zero. In this way, a common change in the copy number of interrogated
F1 offspring relative to the reference DNA was ignored, while probe-
sample pairs at a unique CNV would be substantially deviant from zero.
CNV discovery was executed by three distinct approaches. The first
approach was previously described for the VAMP software (Arlt et al.,
2011a,b). The last two approaches used hidden Markov models (HMMs)
with a series of discrete LRR states at 0, 0.1, −0.1, etc. The emission
probability that an input LRR value would be observed for a candidate
state was calculated from one of two probe standard deviations and the
normal distribution. The first standard deviation was for all probes on a
chromosome in a given sample, which optimally considers sample array
quality. The second standard deviation was for the set of sample LRR
values in the majority group determined above for each probe, which opti-
mally considers probe quality. A maximum allowed LRR deviation of 1.2
and a minimum emission probability of 0.0005 ensured that extreme out-
lier values (i.e. failed probes) did not have an undue influence on the
model. The HMMs further invoked a low transition probability of 0.025,
given that most of the genome, including CNVs, is comprised of runs of
probes in the same copy number state. The Viterbi algorithm was used to
solve each resulting HMM to assign an LRR state to each probe in each
sample.
For maximal sensitivity, consecutive series of at least five probes nomi-
nated as CNVs (average LRR deviation of 0.2 or more) for any animal by
any algorithm were collapsed into overlapping regions. Array data for all
samples were visually examined together at each region in a genome
browser to judge CNV call quality and sample specificity. We used the
same browser interface to visually scan the genome to ensure that obvious
CNVs had not been missed.
CNVDetection andCharacterization byMate-pair
Sequencing
In later studies, we turned to genomic sequencing due to discontinua-
tion of Nimblegen genomic microarrays. Libraries were constructed using
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tail snip DNA and the Illumina (San Diego, CA) Nextera Mate Pair
Library Prep Kit without fragment size selection according to the manufac-
turer’s instructions. Paired end sequencing (read lengths 52 to 66 nt) was
performed at the University of Michigan DNA Sequencing Core on a
HiSeq 2500, pooling four or five samples per lane using standard Illumina
indexing. Reads pairs were first processed by NXTrim (O’Connell et al.,
2015) to assign them to appropriate orientation categories, since read pairs
from mate-pair libraries sometimes cross the circularization ligation junc-
tion and sometimes represent simple genomic fragments. Three samples
were excluded from further analysis based on a much lower yield of circu-
larization junctions, indicative a failed library preparation. Resulting reads
were mapped to the mm10 reference genome using BWA MEM (Li and
Durbin 2010) with default settings. Fragment-level coverage,
i.e., considering the entire length of sequenced DNA fragments assigned
as proper pairs by BWA (SAM flag bit 0x2 set), was typically 30- to
40-fold, providing excellent sensitivity for CNV detection. Base-level,
i.e., read, coverage was typically 1- to 3-fold, providing sufficient informa-
tion on single nucleotide polymorphisms (SNPs) for strain assignment but
insufficient coverage for discovery of de novo point mutations.
Two distinct algorithms were used to nominate structural variants in
aligned reads, using custom software that follows established approaches
and optimizes the detection of CNVs unique to just one sample. To facili-
tate analysis, samples were grouped into sets of six to eight pups of the
same sex where no two animals shared a common parent, so that CNVs
that arose in a parent and were inherited by a sib pair would still be
detected. The first algorithm follows logic patterns based on the relative
spacing and orientation of paired reads (Korbel et al., 2007; Arlt et al.,
2011a,b), for example that the reads of a pair flanking a novel deletion
junction map with a large spacing and a predictable clustering of reads on
each side of the junction. We applied this algorithm simultaneously to all
non-PCR-duplicated anomalous read pairs (i.e. flag bit 0 × 2 not set) from
all samples in a set with a minimum mapping quality of five, which per-
mitted detection as well as assessment of the uniqueness of nonreference
read-pair patterns. Whereas most nonreference patterns were present in all
isogenic animals, patterns unique to one animal were nominated as candi-
date de novo CNVs if they had at least five supporting read pairs and
were < 2 Mb, which suppresses mapping artifacts arising from reads in
repetitive DNA elements. Notably, no unique inversions were found even
though the read pair method is capable of finding them.
For the second algorithm based on fragment depth, we constructed a cov-
erage map of the genome for each set of samples using variable width bins.
Each proper read pair was counted such that each covered position was
incremented by 1 divided by the fragment length. These position values
were summed over all read pairs and samples in a set. Chromosome bins
were assigned from left to right, with bases added to each bin until its
summed count was equal to 100 times the number of samples. Thus, all bins
carry equal and substantial statistical weight. Four samples (three treated,
one untreated) showed a notably larger intrasample variation in bin cover-
age. These samples were excluded from depth analysis as they yielded many
false-positive CNVs but were included in read pair calling. The typical
median bin size was 6 kb, allowing detection of ~25 kb CNVs covering four
consecutive bins. Bin sizes are inversely correlated to the mappability of the
underlying DNA and the modal copy number in the input samples, i.e., the
copy number in typical non-CNV containing animals. We therefore com-
pared all bin sizes to reference span chr1:100000000–200000000, empiri-
cally determined to have a stable copy number of 2. A HMM was
constructed based on the variance of bin sizes in this region and algebraic
expansion to obtain the expected mean and variance for other discrete copy
number states. Solution of this HMM by the Viterbi algorithm assigned a
modal copy number to all bins genomewide. This information permitted cal-
culation of expected read counts for a set of discrete copy number change
(CNC) states (0, +1, −1, etc.) for each sample, based on the median bin
count across all samples after normalizing them to the same scale based on
each sample’s total reads. This median count, which represents the modal
copy number state, is typically ~100 but deviates from that value when one
or more samples have a CNV. For visualization, the CNC of a sample at a
bin was calculated as the population modal copy number multiplied by the
fractional deviation of the sample’s normalized read count relative to the
median count. For CNV detection, a second HMM was constructed and
solved for each sample that used the Poisson distribution and the expected
read counts to determine emission probabilities for each actual bin count,
resulting in an assigned discrete CNC for all bins and samples. CNVs were
called as stretches of four or more bins with a CNC different than zero.
The set of all nominated variants from each method was then assem-
bled and all available evidence was visually examined at each candidate
genomic locus for all samples, including anomalous read pairings, cover-
age depth of proper pairs, and the allelic fraction of known C3H/HeJ SNPs
(Keane et al., 2011), where half of sequenced reads were expected to
match the C3H/HeJ allele under the null hypothesis of a heterozygous
state with a copy number of two. CNVs in only one pup were kept as can-
didate de novo events. As an internal validation, CNVs were consistently
detected by both read pair and depth algorithms except where specific
identifiable factors prevented it. For example, it is not possible to detect
CNVs that arose by NAHR using read pair orientations. Conversely, the
read pair algorithm had higher sensitivity for small events.
Assessment of CNVDe novo Status, Parent ofOrigin, and
Breakpoint Sequences
We first validated that candidate CNVs were real, and not an artifact of
the genomic detection method using droplet digital polymerase chain reac-
tion (PCR) (ddPCR) with the QX-200 ddPCR EvaGreen Supermix (Bio
Rad, Hercules, California). Test primers were designed within the called
CNV. Control primers were designed within a verified copy number
2 region of chromosome 16. ddPCR was performed on DNA from the pup
and a control mouse lacking the called CNV. Validated candidate de novo
CNVs were unique to F1 pups but might have arisen in either parental
germline, or in the mouse colonies that gave rise to the parent animals.
Accordingly, we next examined the parents of each pup with a validated
CNV using the same ddPCR approach. If the CNV was absent from both
of its parents, it was classified as a de novo CNV. Parent of origin of de
novo CNVs could be determined in cases where the CNV spanned one or
more informative SNPs in the pup. PCR amplification of the followed by
Sanger sequencing revealed which allele was affected by the CNV (loss or
gain) and thus, in which parent’s germline the CNV arose. CNV break-
point junctions were amplified using the Expand Long Template PCR Sys-
tem (Roche Applied Science, Indianapolis, IN) as previously described
(Arlt et al., 2009). All products were subjected to standard Sanger
sequencing and the resulting sequence was compared to the reference
genome (build mm9) to identify the breakpoint junctions.
Detection of 39,X (XO)Mice
XO mice with a 39,X karyotype were revealed by mate-pair sequencing
read count ratios of sex chromosomes and autosomes consistent with one
copy of chrX and no copies of chrY, where expected ratios were established
from the cohorts of XX and XY mice. Similar to above, prior knowledge of
SNPs in C3H/HeJ relative to C57BL/6 readily established the parental ori-
gin of the chrX that was present. For follow-up studies of unsequenced
mice, DNA was extracted from tails snips by using the Hot Sodium
Hydroxide and Tris (HotSHOT) method (Truett et al., 2000). Briefly, 75μl
alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA, pH of 12) was added
to 0.2-cm tail snips. Samples were heated to 95 C for 30 minutes, cooled
to 4 C and followed by an addition of 75μl neutralizing reagent (40 mM
Tris–HCl). We first used this DNA and sex determining region Y (SRY)
primers (Forward: 5’-TTGTCTAGAGAGCATGGAGGGCCATGTCAA-30;
Reverse: 5’-CCACTCCTCTGTGACACTTTAGCCCTCCGA-30) to identify
and discard males with a detectable Y chromosome. PCR was performed
on the remaining animals using primers (Forward: 5’-ACACAG-
GAAAGCCCTTGACA-30; Reverse: 5’-TGCACCATCAGCATGCTCTT-
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30) flanking a C57BL/6 chrX SNP rs13483744 that created a restriction
fragment length polymorphism (RFLP) between the two strains. PCR prod-
ucts were cut with Xba I and run on a gel, where XX females showed both
cut and uncut products, whereas paternally derived 39,X females showed
only uncut products. Animals that had been subjected to mate-pair sequenc-
ing where sex chromosome status was known were used to validate the
assay, since no additional 39,X pups were found.
Micronucleated ReticulocyteAssay
For mice treated using gavage, seven dose groups were examined:
0, 50, 55, 60, 65, 70, and 75 mg/kg HU, administered twice daily. Dosing
was maintained for 42 days, after which blood was drawn. For mice trea-
ted using pumps, two experimental groups were used, untreated (N = 5)
and 19.5 mg/kg/hr HU (N = 4). Blood was drawn from the lateral tail vein
with a 21-gauge needle on Day 0 (untreated), Day 1, and Day 3 of treat-
ment and 10 μl analyzed for micronucleated reticulocytes as described in
Hayashi et al. (Hayashi et al., 1990).
DataAvailability
All microarray and mate-pair sequencing data used for interpreting HU
effects have been deposited in NCBI’s Gene Expression Omnibus (Edgar
et al., 2002) under series accession number GSE114754 and Sequence




We performed several trials of HU administration with
the common design strategy outlined in Figure 1. Through-
out, we sought to use the maximally tolerated dose (MTD)
of HU to afford the highest possible likelihood of observ-
ing an effect of HU on de novo CNV formation, where the
dose-limiting toxicity was an inability to sire offspring due
to reduced spermatogenesis or failure to thrive. Blood
plasma drug measurements and reticulocyte micronucleus
assays further informed dosing efficacy. HU was adminis-
tered to male C57BL/6 mice via gavage or subcutaneous
microinfusion pumps in the postnatal reproductive period
during a time window expected to include mitotic divisions
in the germline. Mice treated via gavage received HU for
56 days prior to the initiation of mating. Mice treated via
microinfusion pumps received HU for 14 days and allowed
to recover for 35 post-treatment, during which time cells
undergoing mitotic cell divisions during treatment devel-
oped into mature sperm (Griswold 2016). After the treat-
ment and recovery periods, treated males were mated
alongside untreated controls to C3H/HeJ female mice to
produce hybrid offspring. CNVs were scored in indepen-
dent offspring (at most two per sired litter) by whole-
genomic analysis, either high-density microarray compara-
tive genomic hybridization (aCGH) or low coverage mate-
pair sequencing (see Methods). Digital droplet PCR
(ddPCR) or aCGH was used to assess the presence of
detected CNVs in parents to determine whether CNVs were
de novo or inherited. The cross of C57BL/6 males by
C3H/HeJ females was chosen to ensure a high number and
density of heterozygous polymorphisms for finally deter-
mining the parent of origin of observed CNVs.
HUAdministration andDose Finding byGavage
We first administered HU to mice by oral gavage. Based
on published reports in mice and rats (Rich and De Kretser
1977; Wiger et al., 1995), we estimated that a twice-daily oral
dose of 500 mg/kg would approximate the MTD in mice. We
performed a dose-range finding study with HU doses of
0, 100, 200, 300, 400, 500, and 700 mg/kg given twice daily
to six male mice in each group. For all gavage experiments,
dosing began at postnatal day (PND) 28 and continued for
56 days, at which time mice were mated. Strikingly, all mice
treated with HU at doses greater than 100 mg/kg showed
severe weight loss and distress and were euthanized after
8–12 days of treatment (Fig. 2A). Only the 0 and 100 mg/kg
group mice completed the 56 day trial. There was a clear
effect on weight gain seen at 100 mg/kg but the mice were
otherwise healthy. We attempted to breed four males in each
group. While plugs were noted, indicating successful mating,
none of the 100 mg/kg HU-treated mice sired litters.
C57BL/6 mice are thus very sensitive to the effects of HU in
a 56-day treatment protocol, even at 100 mg/kg HU, a much
lower dose than expected based on published experiments
using shorter treatment periods (Wiger et al., 1995).
A second dose-range finding study was performed using
lower doses of 0, 6, 12, 18, 25, 50, 75, and 100 mg/kg for
56 days. None of these treated mice showed notable ill
effects of drug treatment, although weight gain was
reduced at the highest doses. Mice treated with doses of
HU up to 50 mg/kg sired normal sized litters while the
mice treated with 75 and 100 mg/kg were infertile
(Table I). These results indicated a very narrow range for
the MTD between 50 and 75 mg/kg HU.
A final dose-range finding study used 50, 55, 60, 65,
70, and 75 mg/kg HU twice daily for 56 days. There was a
dose-dependent effect on weight gain consistent with previ-
ous trials (Fig. 2B). As in the previous experiment, mice
treated with 75 mg/kg HU were infertile, but mice were able
to sire litters at all other doses, with 5 out of 5 mice (100%)
treated with 50 mg/kg HU siring litters, and three out of five
mice (60%) siring litters at 60 and 70 mg/kg HU. The
70 mg/kg dose also dramatically reduced litter size
(Table I). Based on mouse weights and breeding capacity, a
dose of 60 mg/kg HU administered twice daily was chosen
for CNV studies. Limitations of this dosing regimen with
respect to pharmacokinetics are discussed below.
Histopathology ofMice TreatedwithHUbyGavage
Male reproductive and hematopoietic tissues from mice
treated with 0, 25, 50, 75, and 100 mg/kg twice daily in the
dose-range finding study were histopathologically assessed
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(Fig. 3A–D). HU-treated mice demonstrated a number of
degenerative changes in the testes, with secondary effects
in the epididymides, in a dose-dependent manner with little
to no functional sperm production at the highest doses. At
100 mg/kg, there was severe atrophy of almost 100% of
the testicular seminiferous tubules, with diffuse depletion
of germ cells and vacuolation of the remaining Sertoli cells
(Fig. 3A). The epididymides contained no sperm. At
75 mg/kg, approximately 75–80% of the tubules had partial
depletion of germ cells, consisting of greatly depleted
round and elongated spermatids (postmeiotic stages) and
decreased spermatocytes. The epididymides had markedly
decreased sperm and increased exfoliated germ cells. At
50 mg/kg (Fig. 3B), there were qualitatively similar effects
of germ cell depletion but only 20–25% of the seminiferous
tubules were affected. The epididymides contained slightly
decreased numbers of sperm. At 25 mg/kg HU, the testes
were almost histologically normal apart from increased
residual bodies and slightly decreased mature spermatids in
~5% of tubules (Fig. 3C). The epididymides.at this dose
had a normal amount of morphologically normal sperm.
Control animals had morphologically normal testes and
epididymides (Fig. 3D).
In contrast to the germline, hematopoietic alterations
were confined to the highest dose (100 mg/kg) mouse,
which had a mildly increased myeloid (granulocytic):
erythroid ratio in the femoral bone marrow and moderately
increased extramedullary hematopoiesis in the spleen. The
increased extramedullary hematopoiesis in the spleen was
predominantly of the erythroid lineage. There were no
hematopoietic alterations in other animals and no lymphoid
alterations in any animal.
In the definitive study for CNV induction, six mice trea-
ted with 60 mg/kg HU and four vehicle-treated controls
were analyzed for testicular or epididymal histopathology
(Fig. 3E–F). Treated mice had significantly smaller abso-
lute and relative (to body weight) testicular weights at nec-
ropsy (mean  S.D. of treated was 0.060 g  0.016 vs
0.103  0.008 for control, P = 0.0018 by unpaired two-
tailed t-test). This was consistent with the histological find-
ings of decreased spermatogenesis (germ cell depletion and
degeneration) in treated animals (Fig. 3E). Germ cell deple-
tion/degeneration manifested as severe depletion of round
and elongating spermatids and moderate to marked
decreases in pachytene spermatocytes. Frequently, there
was luminal sloughing of pachytene spermatocytes with
visible meiotic spindles (Fig. 3E, inset) and the absence of
postmeiotic germ cell stages (spermatids), suggesting mei-
otic arrest. Germ cell depletion/degeneration was present in
all six treated animals and ranged from mild (5–25%
tubules affected, 5 out of animals) to marked (51–75%
tubules affected, 1 of 6 animals), and thus, although
Fig. 1. Overall experimental outline of HU treatment and mating. Male
C57BL/6 mice were treated with HU by either oral gavage (A) or
subcutaneous microinfusion pumps (B). In the former, dosing continued
up to the time of mating, in the latter, mice were allowed to recover for
35 days during which time spermatogenesis completed from stem cells
that were dividing during the treatment period. Common design features
included mating of treated C57BL/6 males with C3H/HeJ females to
produce F1 offspring heterozygous for a large number of polymorphisms
used to assign the parent of origin of CNVs detected by whole-genomic
analysis, either aCGH or low-coverage mate-pair sequencing.
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spermatogenesis was decreased, it was not entirely abol-
ished at the 60 mg/kg dose. Epididymal changes affected
50% (3/6) of treated animals, consisting of decreased
sperm numbers and mildly to moderately increased (above
control levels) sloughed intraluminal germ cells. Despite
the decrease in sperm number, most of the sperm within
the epididymis were morphologically normal, which is
consistent with compound effects on earlier (meiotic
and/or premeiotic) stages of spermatogenesis, as opposed
to abnormalities of spermatid (postmeiotic) maturation.
This observation is also consistent with the ability of the
majority of treated animals to sire offspring (Table I).
Control mice were histologically normal (Fig. 3F), apart
from minor background histologic findings of occasional
tubular atrophy, tubule dilation, and increased residual
bodies, each affecting <5% of tubules. These findings are
commonly seen at low levels as background findings in
normal young mice and were considered unrelated to
treatment (Creasy DM 2002).
CNV Formation inMiceTreatedwithHUbyGavage
A total of 42 male mice were treated by gavage with
60 mg/kg HU b.i.d. for 56 days and bred to females along-
side 24 controls treated with 0 mg/kg HU (water vehicle
only). Weight gain data for treated and control animals are
shown in Fig. 2C. All control males and 34 of 42 (81%)
treated males sired litters, with average litter sizes of 6.1
and 4.9 pups, respectively. This modest decrease in fertility
was consistent with our targeted MTD. Genomic DNA
from 58 pups from HU-treated sires and 22 pups from con-
trol sires was analyzed by microarray. We found more than
20 common polymorphic CNV variants segregating in the
colony, as well as 10 rare CNV variants found in individual
pups but inherited from one parent, indicating that they
were recent, spontaneous de novo CNV mutations arising
during the propagation of these inbred strains (Tables II
and III, Supplemental File S1). Five CNVs were confirmed
to be de novo, i.e., present in only one pup and absent in
both parents. One de novo CNV was maternally-derived in
a pup sired by a control male, while the remaining four
CNVs were in pups sired by treated males. Three of the lat-
ter CNVs were maternally derived, while a single CNV had
an indeterminate parental origin due to a lack of informative
heterozygous SNPs. If the latter CNV were of paternal ori-
gin, the resulting frequency of de novo, paternally-derived
CNVs in treated mice (1/58; 1.72%) and controls (0/22; 0%)
would not significant (P = 1.00, Fisher’s exact test). With
these sample sizes, the smallest detectable significant induc-
tion of CNVs would have been 11/58 (19.0%), due in part
to the low number of control pups tested. In this context, we
chose to test more treated pups than control pups because
some CNVs must be detected in treated animals if a CNV
induction effect were to be possible. Because we observed
no such target CNVs with certainty, further testing of con-
trols pups was not indicated or cost efficient.
Fig. 2. Dose range finding studies weight gain. Weight gain in mice administered with the indicated doses of HU by
gavage (A–C) and microinfusion pumps (D). Weight gain is indicated as a percent change in animal weight compared to
weight at Day 0. HU treatment began on Day 1 and continued through 56 days (gavage) or 14 days (pumps).
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The breakpoint junction from one de novo CNV was
sequenced: a maternally derived, 17.7 kb deletion that showed
5 bp of microhomology between the joined ends (Table IV).
In addition, junctions from two inherited rare variant CNVs
were sequenced. One was a duplication with two base pairs of
microhomology and the other was a deletion with one base
pair of microhomology. In total, the absence of known pater-
nally derived de novo CNVs did not support the hypothesized
induction of germline CNVs by HU. However, lack of HU-
induced CNVs was not due to an inability to detect CNVs;
CNVs could be and were detected, including 4 of 80 (5%)
untreated maternal haplotypes with de novo mutations and
10 rare variants arising in the inbred C57/BL6 or C3H colo-
nies, indicating a high rate of this type of mutation in mice.
To further understand the nature of HU treatment by
gavage, we performed pharmacokinetic analysis of plasma
HU levels after treatment with 60 mg/kg HU (Fig. 4B). Mice
were treated with a single dose of HU and blood samples
taken at time points from 48 to 240 hours postadministration.
HU levels spiked rapidly in the bloodstream, with a peak
concentration of 300 μM within minutes of gavage and was
cleared rapidly, with only trace levels detected at 80 minutes.
TABLE I. Summary of Histopathology and Breeding Capacity of HU-treated Males.
Gavage
HU dose (mg/kg)
Histopathology (testes) # affected/evaluated Severity







6 n.d. 4/4 (100%) 4.7
12 n.d. 4/4 (100%) 6.2




50 Germ cell depletion/degeneration
1/1





55 n.d. 4/5 (80%) 6.7
60 Germ cell depletion/degeneration 6/6





65 n.d. 4/5 (80%) 3.3
70 n.d. 3/5 (60%) 1.7
75 Germ cell depletion/degeneration
1/1






(complete loss of germ cells)
1/1
Grade 5 of 5
0/4 (0%) -
Pumps
HU dose (mg/kg/hr) Histopathology (Testes)
# affected/evaluated
Severity grade (0 to 5)a







8.7 n.d. 2/2 (100%) 5.0










19.5 Germ cell depletion/degeneration
5/5
Grade 1–2 out of 5
18/47 (38%)c 5.93




26.1 n.d. 0/3 (0%) -
34.7 n.d. 1/3 (33%) 2.0
aSee methods for severity grading descriptions.
bRows with multiple data points are from separate dose range finding studies.
cData from definitive studies.
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The elimination rate constant (Ke) was calculated to be
−0.049 with half-life of only 13.97 minutes. This resulted in
essentially only a 20–30 minute treatment window. We rea-
soned that the absence of paternally-derived de novo CNVs
in the offspring of male mice in the gavage experiment could
be the result of this rapid turnover, resulting in long drug-
free periods, even with twice-daily dosing, and inefficient
perturbation of S-phase replication fork progression consid-
ered necessary for CNV formation.
HUAdministration andDose Finding bySubcutaneous
Peristaltic Pumps
To achieve longer windows of persistent replication stress
needed for CNV induction, we turned to programmable
microinfusion pumps (iPRECIO) as an alternate approach for
HU delivery. These battery-operated, surgically implanted
pumps have a refillable reservoir whose contents are released
at small time intervals into subcutaneous tissue, thus adminis-
tering a drug effectively continuously over many days. To test
the pumps, mice were treated with 19.5 mg HU/kg/hr and
plasma HU concentrations were measured at multiple time
points over 10 days (Fig. 4B). A nearly constant, steady state
concentration of HU was observed in the plasma, ranging
from 26 to 40 μM, a marked improvement over oral gavage.
Two 14-day dose range finding studies were conducted
using the pumps, again using male fertility as the primary
endpoint (Fig. 1). The first study used HU doses of 8.7,
13.0, 17.4, 21.7, 26.1, and 34.7 mg/kg/hr. No difference in
weight gain in the animals at different doses was noted dur-
ing the treatment window (Fig. 3D). A large drop in the
number of mice able to sire litters occurred between
21.7 mg/kg/hr, for which ~40% of treated males sired lit-
ters, and 26.1 mg/kg/hr, for which no pups were sired
Fig. 3. Histopathology of testis after HU treatment. Representative images
of seminiferous tubules showing dose-dependent germ cell depletion and
degeneration in mice administered the indicated doses of HU by gavage
(A–F) and microinfusion pumps (G–I). Germ cell depletion in the gavaged
animals ranging from complete loss of germ cells (tubular atrophy)
(asterisk) in the high-dose animal (A, 100 mg/kg) to decreased spermatids
and spermatocytes in a mid-dose animal (B, 50 mg/kg), and minimal
changes apart from a few tubules with mildly decreased elongated
spermatids and increased residual bodies (arrowheads) in the 25 mg/kg
animal (C). Compare to the control animal (D, Stage-VIII tubule) with
numerous mature elongated spermatids (asterisk), immature round
spermatids (rs), and spermatocytes (S). See text for proportion of tubules
affected at each dose. Gavage at 60 mg/kg (E) produced occasional tubular
atrophy (asterisk) and depleted postmeiotic germ cells (spermatids) and
degeneration and sloughing of premeiotic stages (spermatocytes) affecting
up to 75% of tubules. This included luminal sloughing of late-stage
spermatocytes with visible meiotic spindles (arrowheads, inset). Compare
the cell density to that in the control animal (F). Animals receiving
19.5 mg/kg/hr HU by peristaltic pump had mild-to-moderate germ cell
depletion evidenced by increased residual bodies (arrowheads, G) and
decreased spermatocytes and spermatids (H) affecting between 5–25% of
tubules. Compare to the cell density in the control animal (I, Stage-VIII
tubule) showing numerous elongated spermatids (ES), round spermatids
(RS), pachytene spermatocytes (P), and preleptotene spermatocytes
(pl) supported by Sertoli cells (SC). Hematoxylin and eosin-staining. Bars
A–F: 50 μm, G–H: 20 μm.
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(Table I). A large drop in litter size occurred between 13.0
and 17.4 mg/kg/hr, with 8 and ~2.5 pups per litter, respec-
tively. The second dose range study examined additional
concentrations between 13.0 and 21.7 mg/kg/hr. The great-
est decrease in fertility and litter size occurred between
19.5 and 21.7 mg/kg/hr. We therefore chose 19.5 mg/kg/hr
for further studies of CNV induction.
Histopathology ofMiceTreatedwithHUbySubcutaneous
Peristaltic Pumps
In the definitive CNV study, five mice treated with
19.5 mg/kg/hr HU by peristaltic pump and four vehicle-
treated controls were analyzed histopathologically
(Fig. 3G–I). Mice treated with 19.5 mg/kg/hr HU showed
testicular alterations of germ cell depletion/degeneration
that were qualitatively similar to those seen at higher
doses in the gavage studies but were quantitatively much
less severe, since they affected only 1–5% (minimal) or
5–25% (mild) of tubules. Affected tubules contained
decreased elongated and round spermatids (postmeiotic
stages), often with increased luminal or basal residual
bodies (Fig. 3G). There were also decreased or degenerate
pachytene spermatocytes and spermatogonia (Fig. 3H).
Consistent with the small number of tubules affected, the
overall density of sperm in the majority of testicular
tubules was normal or only slightly decreased and the epi-
didymal sperm were normal in quantity and morphology.
There were no alterations in the testes (Fig. 3I) or epididy-
mis of control mice. These observations suggest a reduced













Maximum frequency of paternally
derived CNVsb p-valuec
Gavage 0 mg/kg 22 1 1 0 0 0/22 (0%) -
Gavage 60 mg/kg 58 4 3 0 1 1/58 (1.72%) 1.00
Pump 0 mg/kg/hr 21 0 0 0 0 0/21 (0%) -
Pump 17.4 mg/kg/
hr
42 4 1 1 2 3/42 (7.1%) 0.299
Combined NT 43 1 1 0 0 0/43 (0%) -
Combined Treated 100 8 4 1 3 4/100 (4.00%) 0.316
aParental origin determined by SNP analysis.
bAssumes all CNVs with unknown parental origin are paternal.
cFisher’s exact test, treated compared to untreated in each delivery group.
TABLE III. De novo CNVs
Delivery Mouse HU/Ctrl CNV coordinates (mm10) CNV size (kb) CNV type Parental origina
Gavage F579 Ctrl chr14:74138655-74456451 317 Loss Maternal
Gavage F703 HU chr11:73567353–73578788 11 Gain Unknown
Gavage M707 HU chr12:113978427–113993947 16 Loss Maternal
Gavage M707 HU chr6:124510361–124580524 70 Loss Maternal
Pump 1436x1529p2 HU chr16:8982381–9004906 22 Gain Unknown
Pump 1436x1529p2 HU chr2:16905457–17084790 178 Gain Unknown
Pump 1416x1477p1 HU chr2:70453670–70884498 427 Gain/Complex Paternal
Pump 1442x1475p2 HU chr6:16924886–16947509 22 Gain Maternal
aParental origin determined by SNP analysis.
















M288xF397 Gavage - Rare Gain 6 51,318,090 51,418,183 1 C
M707 Gavage HU De novo Loss 12 113,977,727 113,995,472 5 AACAA
F703 Gavage - Rare Loss 3 82,674,187 82,682,462 2 CT
1416x1477 Pump HU De novo Complex 2 70,881,262 70,968,367 0 -
1416x1477 Pump HU De novo Complex 2 70,453,485 70,968,476 3 GGC
1436x1529 Pump HU De novo Gain 2 16,905,358 17,084,979 5 TG(A/T)GG
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In our first experiment using pumps, 47 males were trea-
ted at 19.5 mg HU /kg/hr subcutaneously from postnatal
day (PND) 28 to 37. These animals were bred to females
for seven days beginning 35 days after the end of the treat-
ment period. From our dose-finding studies, we expected a
fertility rate of ~50% with ~3 pups per litter after HU treat-
ment. In the definitive experiments, we obtained a treated
fertility rate of 38% with 5.8 pups per litter. Control mice
had a fertility rate of 90% with 6.4 pups per litter. Genomic
DNAs from 32 pups from HU-treated sires were analyzed
for de novo CNV mutations by aCGH. In total, there were
three private validated CNVs found in these pups, all of
which proved to be rare population variants inherited from
one parent.
Given the higher than expected number of treated mice
unable to sire litters in this experiment compared to the
dose range finding study and the narrow concentration
range in which HU has an effect, it was possible that sperm
or pups with induced CNVs were being selected against.
We therefore repeated the experiment as above, but with a
slightly reduced HU dose of 17.4 mg/kg/hr. A total of
42 pups sired by treated mice and 21 pups sired by
untreated controls were analyzed for de novo CNVs by
mate pair sequencing. Four de novo CNVs were validated
in this experiment, all arising in pups sired by HU treated
mice (Table II). One of these CNVs was maternally
derived, one was paternally derived, and the remaining two
were of indeterminate parental origin because of a lack of
informative SNPs. To estimate the largest possible HU
effect from these data, we presumptively assigned the inde-
terminate CNVs to the sires. Thus, potentially 3 of 42 pups
from the treatment group had de novo CNVs arising in the
paternal germline, as compared to 0 of 21 control pups.
This difference is not significant for an HU-induction effect
(P = 0.299, Fisher’s exact test), consistent with findings
when HU was administered by oral gavage. Combining the
CNV data from this experiment and the gavage experiment,
assuming all de novo CNVs of unknown parental origin
were paternal, gives a total of 4/100 and 0/43 de novo
CNVs in treated pups and controls, respectively
(P = 0.316, Fisher’s exact test).
Breakpoint junctions from two de novo CNVs were
sequenced. These breakpoints were again characterized by
short stretches of microhomology, characteristic of nonre-
current CNVs (Table IV). One was a 178 kb duplication
with five base pairs of microhomology, the other was a
complex duplication/deletion CNV containing two break-
point junctions, one with three base pairs of microhomol-
ogy and one with a blunt end.
An incidental finding in this last HU experiment was that
two of 42 pups from the initial treatment group had only
one copy of chrX and no copies of chrY, as determined
from sequencing read counts, and thus had a Turner 39,X
karyotype. SNPs established that the maternal C3H/HeJ
chrX was present in both 39,X pups, indicating that a sex
chromosome was lost during spermatogenesis in treated
males. Published rates of 39,X karyotypes in mice of 0.7%
(Russell and Saylors, 1961) and the absence of 39,X karyo-
types in the treatment group suggested the possibility of an
unexpected induction of germline chromosome segregation
defects by HU. However, when we screened additional
pups using sex chromosome-targeted PCR, the final tally of
2 of 113 (1.8%) paternally-derived 39,X pups from treated
sires and 0 of 141 (0%) from control sires was not
Fig. 4. HU pharmacokinetic
profiles. HU levels in plasma were
measured by high-performance
liquid chromatography tandem
mass spectrometry after a single
60 mg/kg dose administered by
gavage (A) or a continuous
19.5 mg/kg/hr dose administered
by subcutaneous infusion pumps
(B). Data are plotted as individual
animal measurements, one per
animal. In contrast to a high
bioavailability and rapid clearance
of HU in mice treated orally, HU
administered by pumps resulted in
a stable continuous HU plasma
level for many days.
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significantly different (P = 0.197, Fisher’s exact test). With
these sample sizes, the smallest detectable significant
induction of paternally-derived 39,X karyotypes at
P < 0.05 would have been 4/113 pups (3.5%).
Genotoxicity Assessment byMicronucleated Reticulocytes
The reproductive deficiencies observed in treated mice
verified a tissue effect of HU administration, but we
sought further validation of a genotoxic effect. We there-
fore assessed different doses and methods of HU adminis-
tration using a peripheral blood reticulocyte micronucleus
assay (Hayashi et al., 1990). 1000 reticulocytes were
evaluated for the presence or absence of micronuclei
using fluorescence staining, expressed as a percentage of
micronucleated reticulocytes (%MNRET). In the animals
treated by gavage for 42 days, untreated controls had a
mean baseline %MNRET of 0.47%. At increasing doses
of HU, the %MNRET increased, up to 2.33% in mice
treated with 75 mg/kg HU (Fig. 5). When HU was admin-
istered by infusion pumps at a target dose of 13.0 to
21.7 mg/kg/hr, mice had an increase in %MNRET that
plateaued by 6–10 day of treatment, with a maximum
value of 3.4% at 21.7 mg/kg/hr (Fig. 5). These data pro-
vide independent confirmation that HU had a substantial
impact on DNA damage as administered in our experi-
mental trials.
DISCUSSION
We treated male mice with HU at a MTD determined by
reproductive potential and monitored CNV formation
genomewide in offspring. Results support several distinct
conclusions with respect to the pharmacologic properties of
HU and a high rate of spontaneous de novo CNV formation
in mammals as outlined below. Most importantly, within
the statistical power of our studies, results fail to support
our entry hypothesis that chronic HU administration would
increase CNV formation during mammalian spermatogene-
sis. As discussed, experimental variables related to the
short HU half-life in mice and HU administration could
have played a substantial role in this result.
Pharmacologic Properties of HU inMice
HU has substantial impacts on growth and testicular
function (Modebe and Ezeh 1995; Wiger et al., 1995;
Berthaut et al., 2008). Using a different delivery method,
there is some evidence that HU has a shorter half-life in the
blood of rodents as compared to humans (Iyamu et al.,
2001). We found each of these effects to be more dramatic
than anticipated, which led to experimental and interpretive
challenges. Published measurements of blood HU follow-
ing intravenous administration suggested a half-life in mice
ranging from 15 to 19 minutes (Iyamu et al., 2001). In con-
trast, blood HU levels after oral administration are poten-
tially influenced by both absorption and elimination. It was
possible that HU would persist longer in the bloodstream
after oral administration, due to delayed absorption through
the stomach. However, we found that the bioavailability of
HU following oral gavage of simple aqueous solutions was
very high, with peak plasma levels obtained in minutes.
The ensuing elimination half-life was approximately
14 minutes. This led to acute high-dose exposure followed
Fig. 5. Micronucleated reticulocytes after HU dosing. To assess the
genotoxic effect of HU, reticulocyte micronuclei were measured after
either 42 days of HU administration by gavage at the indicated doses (A),
or measured at multiple timepoints after administration by infusion pumps
at the indicated doses (B). Data are plotted with individual points for each
animal (circles and triangles) and the mean value (bars). In (B), points are
offset for each dose for clarity; samples were all collected at either 1, 3,
6, 10 or 13 days. A clear dose- or time-dependent increase in micronuclei
was observed in each dosing paradigm.
Environmental and Molecular Mutagenesis. DOI 10.1002/em
709Effects of Hydroxyurea on CNVs
by long drug-free periods following even twice daily oral
dosing that are not experienced by patients given the much
longer half-life of 3–4 hours in humans (Newman et al.,
1997). Importantly, more appropriate long-term sustained
exposure at levels that perturb but do not completely inhibit
DNA replication was readily achieved when HU was
administered by surgically implanted subcutaneous micro-
infusion pumps.
Fig. 6. Detection of CNVs and determination of de novo status. Examples of de novo CNVs detected by (A) aCGH and
(B) mate pair sequencing (see Supplemental File S2 for similar depictions of all CNVs detected in this study). PCR across
breakpoint junctions was used to determine whether a CNV in a pup was inherited from its sire (C) or arose de novo (D).
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We also found that published HU doses tolerated in rats
proved much too high in C57BL/6 mice, especially when
treated by oral gavage. Severe growth suppression and tox-
icity requiring euthanasia were observed at doses above
100 mg/kg, even though doses as high as 400 mg/kg/day
were tolerated by rats, which maintained some spermato-
genesis (Rich and De Kretser 1977). We suspect that these
half-life and dose-tolerance differences reflect a species-
and/or strain-specific difference in HU sensitivity. Most
importantly, HU promoted extreme testicular suppression
in mice with an extremely narrow dose window regardless
of the route of administration. For example, mice pro-
gressed from normal sperm production to complete infertil-
ity when the gavage dose changed from only 50 to
75 mg/kg. This pattern is potentially highly relevant to our
experimental interpretation and for patients, because it
reflects an extreme tissue sensitivity of the testis to HU
exposure, perhaps realized via apoptosis, which could pre-
vent the long-term replication inhibition in spermatogonial
divisions we sought to achieve. Indeed, these highly toxic
effects were observed in oral gavage despite the fact that
animals were only actually exposed to HU during brief
periods of each treatment day. The potential implications of
these toxicity mechanisms are discussed further below.
HighRate ofNonrecurrentDe novoCNV Formation
CNVs and copy number neutral structural variants are
now well established as a major form of genetic variation
in mammals, and are the predominant form when quanti-
fied as the number of affected base pairs. Importantly, the
impact of CNVs on human health is large in part because
of high rates of de novo CNV formation, which have been
estimated in various studies to range from 1.2x10−2 to
3x10−2 (Conrad et al., 2010a,b; Itsara et al., 2010). One
consequence of high CNV mutation rates is evident in clin-
ical genetic practice, as many human genomic disorders in
patients are caused by CNV mutations absent from either
parent (Zhang and Freudenreich, 2007). Indeed, this study
was motivated by the potentially serious implications for
offspring if this rate were to increase due to pharmacologic
exposure, as possibly suggested by our previous findings
that HU at doses comparable to those in treated patients is
a potent inducer of CNVs in normal cells in vitro.
Our studies corroborate observations of de novo CNVs
in human populations by direct measurement of CNV for-
mation in colonies of inbred mice. In our gavage study,
maternally derived de novo CNVs were more frequent than
those arising in treated sires, possibly suggesting a higher
rate of CNV mutation in C3H/HeJ mice than in C57BL/6.
When summed over all experiments and groups (whether
treated or not), we found that 8 of 190 (4.2%) pups
assessed in this study, four from each administration
method, had a de novo CNV. We could also infer a sub-
stantial rate of CNV formation from the appearance of
additional rare variants in the colony that generated our
studied mice. We detected a total of 13 rare variant CNVs
in 190 pups (6.8%). While these rare variants did not arise
in the gametes giving rise to studied pups, they must have
arisen in the approximately 10 breeding generations from
the frozen embryo stocks giving rise to the C57BL/6 and
C3H/HeJ breeding colonies, since only one dam or sire car-
ried them (Taft et al., 2006). Still other CNVs were found
in pups from a subset of crosses, and therefore inherited
from independent parents. Clearly, even inbred mice rap-
idly acquire large-scale genomic structural alterations that
might violate expectations of genetic purity.
Importantly, these collective observations also document
that our studied animals did harbor de novo CNVs, and that
we were able to detect them with appropriate sensitivity.
Thus, we do not believe that the failure to observe an effect
of HU on CNV formation arises from technical issues.
Nevertheless, we almost certainly did fail to detect any
CNVs that were either too small (<~25 kb) or located in
excessively repetitive regions, given that our methods are
known to be least sensitive for detection of expansions or
contractions of genomic repeats.
Most human CNVs, those experimentally induced by
aphidicolin and HU in vitro, and the large majority of CNVs
detected here, are described as non-recurrent because break-
point junctions are created by mechanisms independent of
long stretches of homology, making them essentially unique
in every occurrence. New events of this class were clearly
evident in our data. Recurrent CNVs are generated by essen-
tially the same mutational event in multiple independent
occurrences by NAHR via long homologous repeats. We
did detect one such CNV that segregated within a subset of
mice, which appeared to arise via a segmental duplication
flanking an intervening duplication. Nevertheless, we had
reduced ability to detect such events when there was insuffi-
cient unique intervening sequence to reveal a copy number
change and so we assume our data underrepresent the rate of
spontaneous recurrent CNV formation. This reduced sensi-
tivity was tolerable in the context of our hypothesis that rep-
lication inhibition by HU would induce non-recurrent CNVs
as seen in cell culture experiments.
Lackof CNV Induction byHU
Because of the pharmacologic issues noted above, we
ultimately performed several trials of HU administration
and in no single experiment, or when considered in aggre-
gate, did we reveal an increased rate of de novo CNV for-
mation in treated animals. Thus, our results support the
null hypothesis that HU as administered in these experi-
ments is not a potent germline CNV mutagen, which might
provide some reassurance to patients taking the drug. How-
ever, a number of limitations of our study must be duly
noted. First, for cost reasons our experiments used a rela-
tively small number of total animals in each group. Thus,
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our study was only powered to reveal large fold differences
in CNV formation rates. Such large differences are
observed in tissue culture, but the real effect in the mam-
malian germline might be lesser. For example, our data
cannot rule out a 10% increase in CNV formation rates,
i.e., approximately one additional CNV in ~190 births,
which some might consider a meaningful increase in risk.
There are ways that statistical power could be improved in
future studies, for example by performing high-throughput
genomic assessment of individual sperm using rapidly
expanding single-cell technologies. Our description of
microinfusion pump use and relevant doses will greatly
facilitate such an endeavor.
The window in which developing germ cells are divid-
ing mitotically and subjected to the effects of HU-induced
replication stress extends over 10 days. This is followed
by a long, 35-day period during which sperm mature. Our
study design was based on a similar study using the
direct-DNA damaging agent benzo[a]pyrene (BaP)
(O’Brien et al., 2016). BaP is a direct-acting mutagen
requiring only a single “hit” and a short exposure. HU, on
the other hand, acts indirectly to alter DNA synthesis and
must be present throughout the cell cycle and preferably
several mitotic divisions for effects on CNV formation.
Because HU can delay cell division, it is possible that the
cell cycle and sperm maturation timeline were altered
such that maximum effects of HU on CNVs were not
observed.
Finally, our results may reflect different cellular
responses to HU by cells in vitro and those in vivo. There
are at least two reasons that CNV detection in the HU-
treated mouse germline might occur at a lower fold induc-
tion than in tissue culture. First, the basis of our original
hypothesis was that HU would act in tissues as a partial
mitotic replication inhibitor, allowing the production of
cells from stressed but completed S phases. It does have
this action in vitro at appropriate doses, but it might not
be the predominant effect in tissues even though plasma
levels in treated patients are comparable to those that
cause replication impairment in tissue culture (Newman,
et al., 1997; Arlt et al., 2011a,b). The pharmacologic pat-
terns described earlier suggest that HU has a potent cellu-
lar or tissue toxicity that is mediated acutely, not via
prolonged inhibition over multiple rounds of replication.
This toxicity could be mediated by the sensitive death and
removal of cells experiencing impaired replication or by
other unknown replication-independent mechanisms.
Regardless of the precise mechanism, premeiotic sper-
matogonia and stem cells appear in histopathological anal-
ysis to be highly sensitive to HU leading to their
elimination before replication-dependent effects can be
manifest in gametes. If this toxicity mechanism is not
replication-mediated, HU not be an optimal choice for
determining the effects of replication impairment on
germline CNV formation. Alternatively, programmed
sensitivity of sperm progenitors to inhibited replication
may serve as a valuable defense mechanism against germ-
line genomic instability. Future studies are needed to
probe these important distinctions.
A distinct issue is that 32% and 37% of the CNVs we
have observed induced in tissue culture arise in genomic
hotspots that strongly correspond to large genes in human
fibroblasts and mouse embryonic stem cells, respectively
(Wilson et al., 2015). Moreover, these genes must be
actively transcribed for CNV formation to occur at high
frequency. An initial objective of this study was to see if
similar transcription-dependent patterns might be observed
in the germline. However, we still have incomplete knowl-
edge of the full transcriptional program of cells in the male
germline, specifically with respect to the expression of very
long (>1 Mb) gene isoforms. If transcription of gene long
isoforms is rare in the germline, then the hotspots that con-
tribute to cell culture CNV formation rates might be absent,
which would necessitate even higher animal numbers for
statistically significant results to be obtained. On the other
hand, it is clear that very long gene isoforms are expressed
in other tissues, including fibroblasts, lymphocytes and
most notably the brain. It will therefore be of considerable
interest to explore the impact of HU exposure on somatic
CNV formation in tissues that had cells dividing during the
time of HU exposure.
Comparison toOtherGermlineCNVStudies
Only one earlier study examined induced germline
CNVs in mice. Adewoye et al. (Adewoye et al., 2015)
found a significant, eightfold increase in the frequency of
de novo CNVs and 2.4-fold increase in de novo indels in
offspring of male mice irradiated with 3Gy of X-rays dur-
ing spermatogenesis. Matings were initiated 8 weeks or
4 days postirradiation, enabling the study of mutation
induction at pre- and postmeiotic stages of spermatogene-
sis, respectively. De novo CNVs were observed in both
groups with the highest frequency in offspring of males
irradiated during mitotic division stages of spermatogene-
sis. Among the 14 unique germline CNV mutations found
in the offspring of irradiated males, 12 were deletions and
two were duplications, with an enrichment for very large
deletions (>1 Mb) with the loss of up to 80 genes. In this
experiment, there was less enrichment for gains, with three
deletions and five duplication, including one complex gain.
The de novo CNV frequency in controls was 1/93 pups
(freq. 0.011), which is lower than the frequency of 0.042
we describe here. This study utilized treated C57BL6/J
males crossed to CBA/Ca females, while our study utilized
C3H females. Since most of the spontaneous CNVs in our
study were maternal in origin, it is possible that spontane-
ous CNV frequency could differ between mouse stains,
thus contributing to this difference.
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